[
  {
    "ts": "2025-11-18T08:30:00+00:00",
    "headline": "[Latest] Global NUT Midline Carcinoma Treatment Market Size/Share Worth USD 93.34 Billion by 2034 at a 15.26% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT)",
    "summary": "[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global NUT Midline Carcinoma Treatment Market size & share revenue was valued at approximately USD 22.67 Billion in 2024 and is expected to reach USD 26.13 Billion in 2025 and is expected to reach around USD 93.34 Billion by 2034, at a CAGR of 15.26% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Merck & Co.",
    "url": "https://finance.yahoo.com/news/latest-global-nut-midline-carcinoma-083000107.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "a44e377f-4362-3d10-a37c-7c7e8b8b2108",
      "content": {
        "id": "a44e377f-4362-3d10-a37c-7c7e8b8b2108",
        "contentType": "STORY",
        "title": "[Latest] Global NUT Midline Carcinoma Treatment Market Size/Share Worth USD 93.34 Billion by 2034 at a 15.26% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT)",
        "description": "",
        "summary": "[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global NUT Midline Carcinoma Treatment Market size & share revenue was valued at approximately USD 22.67 Billion in 2024 and is expected to reach USD 26.13 Billion in 2025 and is expected to reach around USD 93.34 Billion by 2034, at a CAGR of 15.26% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Merck & Co.",
        "pubDate": "2025-11-18T08:30:00Z",
        "displayTime": "2025-11-18T08:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/0bec09301614ea6a3ee415db83086891",
          "originalWidth": 2514,
          "originalHeight": 1281,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/2CrZC42kgw2SjdY2CY6ucw--~B/aD0xMjgxO3c9MjUxNDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/0bec09301614ea6a3ee415db83086891.cf.webp",
              "width": 2514,
              "height": 1281,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/91DUI4_rVm8Et9pJYV6I4Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/0bec09301614ea6a3ee415db83086891.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/latest-global-nut-midline-carcinoma-083000107.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/latest-global-nut-midline-carcinoma-083000107.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "CCCC"
            },
            {
              "symbol": "GSK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-18T11:45:00+00:00",
    "headline": "Merck’s WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint in Phase 2 CADENCE Study in Adults With Combined Post- and Precapillary Pulmonary Hypertension (CpcPH) due to Heart Failure With Preserved Ejection Fraction (HFpEF)",
    "summary": "RAHWAY, N.J., November 18, 2025--Merck’s WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint in Phase 2 CADENCE Study in Adults With CpcPH due to HFpEF",
    "url": "https://finance.yahoo.com/news/merck-winrevair-sotatercept-csrk-met-114500689.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "ebe48e57-ea09-3592-b695-a8ff9aefa284",
      "content": {
        "id": "ebe48e57-ea09-3592-b695-a8ff9aefa284",
        "contentType": "STORY",
        "title": "Merck’s WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint in Phase 2 CADENCE Study in Adults With Combined Post- and Precapillary Pulmonary Hypertension (CpcPH) due to Heart Failure With Preserved Ejection Fraction (HFpEF)",
        "description": "",
        "summary": "RAHWAY, N.J., November 18, 2025--Merck’s WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint in Phase 2 CADENCE Study in Adults With CpcPH due to HFpEF",
        "pubDate": "2025-11-18T11:45:00Z",
        "displayTime": "2025-11-18T11:45:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/77b164c0949222ee521200a66eb4d9c0",
          "originalWidth": 480,
          "originalHeight": 217,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kDxaR_gKXrmDDSq8uxwjjA--~B/aD0yMTc7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/77b164c0949222ee521200a66eb4d9c0.cf.webp",
              "width": 480,
              "height": 217,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/GhmQ1_LUyiD7ZA3ygxO1yA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/77b164c0949222ee521200a66eb4d9c0.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/merck-winrevair-sotatercept-csrk-met-114500689.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/merck-winrevair-sotatercept-csrk-met-114500689.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-18T11:08:42+00:00",
    "headline": "Is Merck's Recent FDA Approval a Game Changer for Its Share Price?",
    "summary": "Thinking about whether Merck is a bargain or not? You’re not alone, plenty of investors are eager to know if now is the time to buy, hold, or stay away. Over the last month, Merck’s share price has jumped 9.5% and gained 7.0% this week alone, even though it’s still down 6.4% year-to-date. Recent headlines have highlighted Merck’s expanding drug pipeline and a new FDA approval, fueling a bit of optimism and helping offset earlier caution in the market. These developments have given more...",
    "url": "https://finance.yahoo.com/news/mercks-recent-fda-approval-game-110842446.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "bf1b1f40-59e9-3fd9-9d82-972b6fea0746",
      "content": {
        "id": "bf1b1f40-59e9-3fd9-9d82-972b6fea0746",
        "contentType": "STORY",
        "title": "Is Merck's Recent FDA Approval a Game Changer for Its Share Price?",
        "description": "",
        "summary": "Thinking about whether Merck is a bargain or not? You’re not alone, plenty of investors are eager to know if now is the time to buy, hold, or stay away. Over the last month, Merck’s share price has jumped 9.5% and gained 7.0% this week alone, even though it’s still down 6.4% year-to-date. Recent headlines have highlighted Merck’s expanding drug pipeline and a new FDA approval, fueling a bit of optimism and helping offset earlier caution in the market. These developments have given more...",
        "pubDate": "2025-11-18T11:08:42Z",
        "displayTime": "2025-11-18T11:08:42Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/d7ea461ebd942c5c61a3f68254dc45cf",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kA84g.s9IO2ClCgTX6BCgg--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/d7ea461ebd942c5c61a3f68254dc45cf.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/DmY770n7xz5DXLM6ZHLmxA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/d7ea461ebd942c5c61a3f68254dc45cf.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/mercks-recent-fda-approval-game-110842446.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/mercks-recent-fda-approval-game-110842446.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-18T15:16:00+00:00",
    "headline": "Fanconi Anemia Market Research Report 2025-2035: Competitive Growth Driven by Rocket Pharmaceuticals, Foresee, Merck, and Abeona as Gene Therapy and CRISPR-Based Innovations Expand",
    "summary": "**Fanconi Anemia Market Growth Driven by Genetic Research and Healthcare Investments**Fanconi Anemia (FA) is a rare genetic disorder impacting bone marrow's ability to produce blood cells, leading to pancytopenia and increased cancer risk due to DNA repair defects. Although incurable, treatments like bone marrow transplants and gene therapy aim to manage FA's symptoms. The rising prevalence of genetic disorders and advancements in genetic research drive the FA market. Key players such as Rocket",
    "url": "https://finance.yahoo.com/news/fanconi-anemia-market-research-report-151600389.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "d61b4673-972b-3918-bef0-e8723e89a643",
      "content": {
        "id": "d61b4673-972b-3918-bef0-e8723e89a643",
        "contentType": "STORY",
        "title": "Fanconi Anemia Market Research Report 2025-2035: Competitive Growth Driven by Rocket Pharmaceuticals, Foresee, Merck, and Abeona as Gene Therapy and CRISPR-Based Innovations Expand",
        "description": "",
        "summary": "**Fanconi Anemia Market Growth Driven by Genetic Research and Healthcare Investments**Fanconi Anemia (FA) is a rare genetic disorder impacting bone marrow's ability to produce blood cells, leading to pancytopenia and increased cancer risk due to DNA repair defects. Although incurable, treatments like bone marrow transplants and gene therapy aim to manage FA's symptoms. The rising prevalence of genetic disorders and advancements in genetic research drive the FA market. Key players such as Rocket",
        "pubDate": "2025-11-18T15:16:00Z",
        "displayTime": "2025-11-18T15:16:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc",
          "originalWidth": 480,
          "originalHeight": 58,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_MlAqEncKPaKK77zrkRGmQ--~B/aD01ODt3PTQ4MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 480,
              "height": 58,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/caWFqk489OEmv3xI33JamQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/fanconi-anemia-market-research-report-151600389.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/fanconi-anemia-market-research-report-151600389.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "RCKT"
            },
            {
              "symbol": "ABEO"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-18T15:59:06+00:00",
    "headline": "Merck Jumps On A Surprise Win; Why It Still Has A Long Road To Go",
    "summary": "Merck stock jumped Tuesday on a surprise win for its drug, sotatercept, in patients with pulmonary hypertension.",
    "url": "https://www.investors.com/news/technology/merck-stock-pulmonary-hypertension-sotatercept/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "fe882aaf-1052-3e81-b59b-fa2730bc7272",
      "content": {
        "id": "fe882aaf-1052-3e81-b59b-fa2730bc7272",
        "contentType": "STORY",
        "title": "Merck Jumps On A Surprise Win; Why It Still Has A Long Road To Go",
        "description": "",
        "summary": "Merck stock jumped Tuesday on a surprise win for its drug, sotatercept, in patients with pulmonary hypertension.",
        "pubDate": "2025-11-18T15:59:06Z",
        "displayTime": "2025-11-18T15:59:06Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/fe882aaf-1052-3e81-b59b-fa2730bc7272/merck-jumps-on-a-surprise.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/f65b6af95194f103ecd03391cd44e98a",
          "originalWidth": 1000,
          "originalHeight": 563,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/R1wF47Whv.ue3OIpmU9hWQ--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/f65b6af95194f103ecd03391cd44e98a.cf.webp",
              "width": 1000,
              "height": 563,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/oOK7lLz4IvjrK7DA2gwCKg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/f65b6af95194f103ecd03391cd44e98a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/news/technology/merck-stock-pulmonary-hypertension-sotatercept/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-18T15:26:00+00:00",
    "headline": "Merck Stock Rises as Heart-Drug Test Offers Hope for Post-Keytruda Era",
    "summary": "The company reported positive results from a trial of the heart drug that the company is counting on for much of its growth.",
    "url": "https://www.barrons.com/articles/merck-stock-winrevair-keytruda-cf15efa2?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "7c652406-cc2a-3a3c-83d6-afef10b8d87d",
      "content": {
        "id": "7c652406-cc2a-3a3c-83d6-afef10b8d87d",
        "contentType": "STORY",
        "title": "Merck Stock Rises as Heart-Drug Test Offers Hope for Post-Keytruda Era",
        "description": "",
        "summary": "The company reported positive results from a trial of the heart drug that the company is counting on for much of its growth.",
        "pubDate": "2025-11-18T15:26:00Z",
        "displayTime": "2025-11-18T15:26:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/7c652406-cc2a-3a3c-83d6-afef10b8d87d/merck-stock-rises-as.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/9260834b83e8e1ecb64fda105ca1c5bf",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/HEESIgcMoTcHryPNvpvYGQ--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/9260834b83e8e1ecb64fda105ca1c5bf.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kUoKbmedfUamAmA0Bh5G0Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/9260834b83e8e1ecb64fda105ca1c5bf.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/merck-stock-winrevair-keytruda-cf15efa2?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "CDTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-18T16:30:00+00:00",
    "headline": "Merck Announces First-Quarter 2026 Dividend",
    "summary": "RAHWAY, N.J., November 18, 2025--Merck Announces First-Quarter 2026 Dividend",
    "url": "https://finance.yahoo.com/news/merck-announces-first-quarter-2026-163000756.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "da870307-8d02-360c-aad1-1a84aca6102f",
      "content": {
        "id": "da870307-8d02-360c-aad1-1a84aca6102f",
        "contentType": "STORY",
        "title": "Merck Announces First-Quarter 2026 Dividend",
        "description": "",
        "summary": "RAHWAY, N.J., November 18, 2025--Merck Announces First-Quarter 2026 Dividend",
        "pubDate": "2025-11-18T16:30:00Z",
        "displayTime": "2025-11-18T16:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/44b58a5b0ddd99a9d493ea4b4c8a343a",
          "originalWidth": 480,
          "originalHeight": 217,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/D4RzZUSG_AGJW8frWuNKUw--~B/aD0yMTc7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/44b58a5b0ddd99a9d493ea4b4c8a343a.cf.webp",
              "width": 480,
              "height": 217,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/fP1YCpRcpXQMSkJCZJH7xA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/44b58a5b0ddd99a9d493ea4b4c8a343a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/merck-announces-first-quarter-2026-163000756.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/merck-announces-first-quarter-2026-163000756.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-18T11:37:00+00:00",
    "headline": "Merck’s blockbuster-to-be cardiovascular drug scores in another heart study",
    "summary": "Winrevair, which Merck has identified as a “growth driver,” significantly improved blood flow through the lungs to the heart in a study of adults with a common form of heart failure.",
    "url": "https://www.biopharmadive.com/news/merck-winrevair-hfpef-heart-cardio-phase-2-data/805798/",
    "source": "BioPharma Dive",
    "provider": "yfinance",
    "raw": {
      "id": "158c58ec-a452-33d2-936c-58ae5af4be2b",
      "content": {
        "id": "158c58ec-a452-33d2-936c-58ae5af4be2b",
        "contentType": "STORY",
        "title": "Merck’s blockbuster-to-be cardiovascular drug scores in another heart study",
        "description": "",
        "summary": "Winrevair, which Merck has identified as a “growth driver,” significantly improved blood flow through the lungs to the heart in a study of adults with a common form of heart failure.",
        "pubDate": "2025-11-18T11:37:00Z",
        "displayTime": "2025-11-18T11:37:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/biopharma_dive_768/f536adfcd024c2ae6c05e4ae6ca107b3",
          "originalWidth": 1600,
          "originalHeight": 900,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/tcrK45LAKfzn0PEIxEu0iQ--~B/aD05MDA7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/biopharma_dive_768/f536adfcd024c2ae6c05e4ae6ca107b3.cf.webp",
              "width": 1600,
              "height": 900,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/JQx6XDLnkdRABWmuOWD50g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/biopharma_dive_768/f536adfcd024c2ae6c05e4ae6ca107b3.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "BioPharma Dive",
          "url": "https://biopharmadive.com/"
        },
        "canonicalUrl": {
          "url": "https://www.biopharmadive.com/news/merck-winrevair-hfpef-heart-cardio-phase-2-data/805798/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/merck-blockbuster-cardiovascular-drug-scores-113700638.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-18T16:03:00+00:00",
    "headline": "J&J Joins Pharma M&A Bandwagon, to Buy Cancer Biotech for $3.05B",
    "summary": "J&J's $3.05B move for Halda adds targeted oral cancer therapies and expands its prostate cancer pipeline amid rising pharma M&A.",
    "url": "https://finance.yahoo.com/news/j-j-joins-pharma-m-160300242.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "3c349984-2127-394c-af6e-5b9be1a63904",
      "content": {
        "id": "3c349984-2127-394c-af6e-5b9be1a63904",
        "contentType": "STORY",
        "title": "J&J Joins Pharma M&A Bandwagon, to Buy Cancer Biotech for $3.05B",
        "description": "",
        "summary": "J&J's $3.05B move for Halda adds targeted oral cancer therapies and expands its prostate cancer pipeline amid rising pharma M&A.",
        "pubDate": "2025-11-18T16:03:00Z",
        "displayTime": "2025-11-18T16:03:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/ca9d72216d7bb42fc496430c3df29b41",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hD1XqSSX7ulRknhxAtE3Fg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ca9d72216d7bb42fc496430c3df29b41.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/WurdES47e08.qoEQbQD.wQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ca9d72216d7bb42fc496430c3df29b41.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/j-j-joins-pharma-m-160300242.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/j-j-joins-pharma-m-160300242.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-18T19:43:08+00:00",
    "headline": "Drug Giant Merck Breaks Out Past New Buy Point; CME, Marathon Eye Entries",
    "summary": "Dow Jones drug giant Merck is breaking out past its latest buy point as the stock market volatility continues Tuesday.",
    "url": "https://www.investors.com/stock-lists/stocks-near-a-buy-zone/dow-jones-merck-stock-mrk-buy-point/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "4c386f44-f75e-36cf-a426-e3e74c0eae5e",
      "content": {
        "id": "4c386f44-f75e-36cf-a426-e3e74c0eae5e",
        "contentType": "STORY",
        "title": "Drug Giant Merck Breaks Out Past New Buy Point; CME, Marathon Eye Entries",
        "description": "",
        "summary": "Dow Jones drug giant Merck is breaking out past its latest buy point as the stock market volatility continues Tuesday.",
        "pubDate": "2025-11-18T19:43:08Z",
        "displayTime": "2025-11-18T19:43:08Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/4c386f44-f75e-36cf-a426-e3e74c0eae5e/drug-giant-merck-breaks-out.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/f4a933d97db0e3f59b1f1f458c35e9cc",
          "originalWidth": 1000,
          "originalHeight": 563,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/s47hMvRMhfinu9_bQ7wo4Q--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/f4a933d97db0e3f59b1f1f458c35e9cc.cf.webp",
              "width": 1000,
              "height": 563,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/GR.uOyiTJtW07DYipi67Jg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/f4a933d97db0e3f59b1f1f458c35e9cc.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/stock-lists/stocks-near-a-buy-zone/dow-jones-merck-stock-mrk-buy-point/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "CME"
            },
            {
              "symbol": "MPC"
            },
            {
              "symbol": "^DJI"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-18T11:30:00+00:00",
    "headline": "Johnson & Johnson Buys Prostate Cancer Treatment-Maker Halda for $3.1 Billion",
    "summary": "J&J this year lost its patent exclusivity for Stelara, its longtime top-selling drug that treats psoriasis and inflammatory bowel disease.",
    "url": "https://www.thedailyupside.com/industries/healthcare/johnson-johnson-acquires-halda-therapeutics-for-3-1-billion/",
    "source": "The Daily Upside",
    "provider": "yfinance",
    "raw": {
      "id": "82ba981b-22f8-3d5f-a945-39f38962987e",
      "content": {
        "id": "82ba981b-22f8-3d5f-a945-39f38962987e",
        "contentType": "STORY",
        "title": "Johnson & Johnson Buys Prostate Cancer Treatment-Maker Halda for $3.1 Billion",
        "description": "",
        "summary": "J&J this year lost its patent exclusivity for Stelara, its longtime top-selling drug that treats psoriasis and inflammatory bowel disease.",
        "pubDate": "2025-11-18T11:30:00Z",
        "displayTime": "2025-11-18T11:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/the_daily_upside_435/32a4da166e1918b112ac336e922dc839",
          "originalWidth": 1600,
          "originalHeight": 901,
          "caption": "The front of a Johnson and Johnson office with modern, angular architecture is shown against a blue sky.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/HVRWQr02vklFH3cgY2t8rw--~B/aD05MDE7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/the_daily_upside_435/32a4da166e1918b112ac336e922dc839.cf.webp",
              "width": 1600,
              "height": 901,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/zGgYJfHEl4OsuiSWzuOHzA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/the_daily_upside_435/32a4da166e1918b112ac336e922dc839.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Daily Upside",
          "url": "http://thedailyupside.com/"
        },
        "canonicalUrl": {
          "url": "https://www.thedailyupside.com/industries/healthcare/johnson-johnson-acquires-halda-therapeutics-for-3-1-billion/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/johnson-johnson-buys-prostate-cancer-113000302.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "AZN"
            },
            {
              "symbol": "AZNCF"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-18T19:22:00+00:00",
    "headline": "Merck Writes a $9.2 Billion Check for a Flu Drug That Could Change Everything",
    "summary": "Merck's multi-billion-dollar acquisition of Cidara Therapeutics is a strategic move to secure a new era of growth with a high-potential antiviral asset.",
    "url": "https://www.marketbeat.com/originals/merck-writes-a-92-billion-check-for-a-flu-drug-that-could-change-everything/?utm_source=yahoofinance&utm_medium=yahoofinance",
    "source": "MarketBeat",
    "provider": "yfinance",
    "raw": {
      "id": "5ec1de8d-434e-3870-94ce-ab6abd3fac00",
      "content": {
        "id": "5ec1de8d-434e-3870-94ce-ab6abd3fac00",
        "contentType": "STORY",
        "title": "Merck Writes a $9.2 Billion Check for a Flu Drug That Could Change Everything",
        "description": "",
        "summary": "Merck's multi-billion-dollar acquisition of Cidara Therapeutics is a strategic move to secure a new era of growth with a high-potential antiviral asset.",
        "pubDate": "2025-11-18T19:22:00Z",
        "displayTime": "2025-11-18T19:22:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/marketbeat_955/e3a7c2d55577e8ed9bd577f3703f1b65",
          "originalWidth": 1200,
          "originalHeight": 675,
          "caption": "Merck’s $9.2B check to Cidara sits with flu vaccine and pills, highlighting its strategic antiviral investment.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Qd_Ul1rjMNUgww2dtebOIQ--~B/aD02NzU7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/marketbeat_955/e3a7c2d55577e8ed9bd577f3703f1b65.cf.webp",
              "width": 1200,
              "height": 675,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/oS6kgYnbsfq7OiVGIB57sw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/marketbeat_955/e3a7c2d55577e8ed9bd577f3703f1b65.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "MarketBeat",
          "url": "https://www.marketbeat.com/"
        },
        "canonicalUrl": {
          "url": "https://www.marketbeat.com/originals/merck-writes-a-92-billion-check-for-a-flu-drug-that-could-change-everything/?utm_source=yahoofinance&utm_medium=yahoofinance",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/merck-writes-9-2-billion-192200009.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "CDTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]